EP3284480A4 - Composition pharmaceutique pour la prévention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 - Google Patents

Composition pharmaceutique pour la prévention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 Download PDF

Info

Publication number
EP3284480A4
EP3284480A4 EP16780054.9A EP16780054A EP3284480A4 EP 3284480 A4 EP3284480 A4 EP 3284480A4 EP 16780054 A EP16780054 A EP 16780054A EP 3284480 A4 EP3284480 A4 EP 3284480A4
Authority
EP
European Patent Office
Prior art keywords
antagonist
prevention
treatment
pharmaceutical composition
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16780054.9A
Other languages
German (de)
English (en)
Other versions
EP3284480A1 (fr
Inventor
Akihisa Kaneko
Yuki IWAYANAGI
Hidetomo Kitamura
Yoshinobu Higuchi
Hiroaki Matsushita
Ryosuke MIHARA
Yumi Yamamoto
Tomohisa Saito
Keiko HIROKAWA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of EP3284480A1 publication Critical patent/EP3284480A1/fr
Publication of EP3284480A4 publication Critical patent/EP3284480A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
EP16780054.9A 2015-04-14 2016-04-13 Composition pharmaceutique pour la prévention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 Pending EP3284480A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015082699 2015-04-14
JP2016041641 2016-03-04
PCT/JP2016/061859 WO2016167263A1 (fr) 2015-04-14 2016-04-13 Composition pharmaceutique pour la prévention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31

Publications (2)

Publication Number Publication Date
EP3284480A1 EP3284480A1 (fr) 2018-02-21
EP3284480A4 true EP3284480A4 (fr) 2018-12-05

Family

ID=57126544

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16780054.9A Pending EP3284480A4 (fr) 2015-04-14 2016-04-13 Composition pharmaceutique pour la prévention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31

Country Status (12)

Country Link
US (2) US10544227B2 (fr)
EP (1) EP3284480A4 (fr)
JP (5) JP6654967B2 (fr)
KR (1) KR20170134748A (fr)
CN (1) CN107614016B (fr)
BR (1) BR112017022101A2 (fr)
CA (1) CA2980992C (fr)
MA (1) MA43918A (fr)
MX (2) MX2017013141A (fr)
RU (1) RU2749512C2 (fr)
TW (3) TW202327654A (fr)
WO (1) WO2016167263A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170134748A (ko) 2015-04-14 2017-12-06 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
WO2017126488A1 (fr) * 2016-01-18 2017-07-27 持田製薬株式会社 Composition de traitement du psoriasis et procédé de traitement
WO2018156180A1 (fr) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anticorps anti-il31 à usage vétérinaire
BR112020016144A2 (pt) * 2018-02-09 2020-12-15 Nestlé Skin Health Sa Nemolizumabe no tratamento de dermatite atópica com escoriação moderada a grave
EP3797752A4 (fr) 2018-05-21 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Formulation lyophilisée scellée dans un flacon en verre
JP2022545259A (ja) * 2019-08-29 2022-10-26 キンドレッド バイオサイエンシズ インコーポレイテッド 動物用の抗ｉｌ３１抗体
CN110563844A (zh) * 2019-09-04 2019-12-13 华中农业大学 一种抗犬白介素31受体的多克隆抗体及其应用
CN114728064A (zh) 2019-11-20 2022-07-08 中外制药株式会社 含抗体制剂
US20230047844A1 (en) * 2020-01-24 2023-02-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Compounds and methods for treating or reducing pruritus
JPWO2022113316A1 (fr) * 2020-11-30 2022-06-02
CN115181183B (zh) * 2022-06-23 2023-11-03 恺佧生物科技(上海)有限公司 一种il-31ra抗体以及其构建方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734549A1 (fr) * 2011-07-21 2014-05-28 Zoetis LLC Anticorps monoclonal dirigé contre l'interleukine-31

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH575014A5 (fr) 1973-05-25 1976-04-30 Alusuisse
JPS5328498Y2 (fr) 1973-08-17 1978-07-18
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
BR9204244A (pt) 1992-10-26 1994-05-03 Cofap Ferro fundido cinzento
EP0671951A4 (fr) 1992-12-01 1997-05-21 Protein Design Labs Inc Anticorps humanises reagissant avec l-selectine.
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
FR2729855A1 (fr) 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
AU690474B2 (en) 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
CN1241944A (zh) 1996-12-05 2000-01-19 乔治敦大学 具有抗病毒活性的鼠尾草种类的提取物
JPH11101542A (ja) 1997-09-29 1999-04-13 Sanyo Electric Co Ltd 冷蔵庫
EP1073683B1 (fr) 1998-04-30 2005-12-28 Tanox, Inc. Anticorps agonistes pour le recepteur g-fsc et procede de criblage associe
FR2780062B1 (fr) 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
EP1088831A4 (fr) 1998-06-24 2003-01-02 Chugai Pharmaceutical Co Ltd Nouvelles proteines receptrices d'hemopo etine
WO2000034317A2 (fr) 1998-12-08 2000-06-15 Biovation Limited Modification de l'immunogenicite de proteines
DK1188830T3 (da) 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd Nyt hæmopoietinreceptorprotein NR10
WO2001023556A1 (fr) 1999-09-27 2001-04-05 Chugai Seiyaku Kabushiki Kaisha Nouvelle proteine receptrice d'hemopoietine (nr12)
CN1326880A (zh) 2000-06-06 2001-12-19 周伟中 双层站台火车站
WO2002000721A2 (fr) 2000-06-26 2002-01-03 Zymogenetics, Inc. Zcytor17, recepteur de la cytokine
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
WO2002077230A1 (fr) 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
DE60229509D1 (de) 2001-04-05 2008-12-04 Astellas Pharma Inc Anti-osteopontin-antikörper und dessen verwendung
EP2840089A1 (fr) 2002-01-18 2015-02-25 ZymoGenetics, Inc. Multimères Zcytor17 du récepteur de la cytokine
PL211833B1 (pl) 2002-01-18 2012-06-29 Zymogenetics Inc Wyizolowany polipeptyd, białko fuzyjne, wyizolowana cząsteczka polinukleotydu, wektor ekspresji, hodowana komórka, sposób wytwarzania polipeptydu, sposób wytwarzania przeciwciała, przeciwciało, przeciwciało lub fragment przeciwciała, zastosowanie przeciwciała, sposób wykrywania obecności polipeptydu, sposób inhibicji proliferacji lub różnicowania komórek krwiotwórczych, zastosowanie polipeptydu, sposób rozprzestrzeniania komórek krwiotwórczych, sposób wykrywania obecności RNA, sposób zabijania komórek nowotworowych in vitro lub in vivo, zastosowanie polipeptydu, zastosowanie antagonisty polipeptydu i sposób wykrywania zapalenia u pacjenta
EP1485477B1 (fr) 2002-02-25 2009-05-13 Genentech, Inc. Nouveau recepteur glm-r de cytokine de type 1
RU2345789C2 (ru) 2002-05-01 2009-02-10 Шеринг Акциенгезельшафт Новые антитела к тканевому фактору в качестве антикоагулянтов
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
KR100499989B1 (ko) 2002-12-27 2005-07-07 네오바이오다임 주식회사 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법
US20040223970A1 (en) 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
WO2004091543A2 (fr) 2003-03-04 2004-10-28 Alexion Pharmaceuticals, Inc. Procede de traitement de maladies auto-immunes en suscitant une presentation d'antigenes par des cellules presentant des antigenes inductrices de tolerance
CN103864934A (zh) 2003-03-24 2014-06-18 津莫吉尼蒂克斯公司 抗il-22ra抗体和结合伴侣以及在炎症中的使用方法
CA2555340A1 (fr) 2004-02-12 2005-09-01 Lexicon Genetics Incorporated Nouvelles disruptions geniques, compositions et procedes associes
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
WO2006004663A2 (fr) 2004-06-25 2006-01-12 Medimmune, Inc. Augmentation de la production d'anticorps de recombinaison dans des cellules de mamiferes par mutagenese sur le site
EP1671642A1 (fr) 2004-12-15 2006-06-21 Universite D'angers Composés contenant des (ant)agonistes de l'oncostatin M (OSM), IL-31 et IFN-gamma pour moduler la migration et fonction de keratinocytes au moyen d'un recepteur comprenant l'OSMRbeta comme sousunité, et applications correspondantes
EP1831258B2 (fr) 2004-12-28 2023-06-07 Innate Pharma S.A. Anticorps monoclonaux contre le nkg2a
EP1848737B1 (fr) 2005-01-28 2016-05-18 ZymoGenetics, Inc. Preparations homogenes d'il-31
CA2595939C (fr) 2005-02-14 2014-08-19 Zymogenetics Inc. Procedes de prediction de reponse therapeutiques dans la dermatite atopique aux antagonistes il-31
WO2006088855A1 (fr) 2005-02-14 2006-08-24 Zymogenetics, Inc. Méthodes de traitement d’affections de la peau en employant un antagoniste de il-31ra
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
JP5065253B2 (ja) 2005-05-06 2012-10-31 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１モノクローナル抗体とその使用法
EP2749571A3 (fr) 2006-01-10 2014-08-13 ZymoGenetics, Inc. Procédés de traitement de la douleur et de l'inflammation dans des tissus neuronaux au moyen d'antagonistes IL-31RA et OSMRb
WO2007084321A2 (fr) 2006-01-12 2007-07-26 Alexion Pharmaceuticals, Inc. Anticorps dirigés contre ox-2/cd200 et utilisations correspondantes
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
JP5043008B2 (ja) 2006-06-08 2012-10-10 中外製薬株式会社 炎症性疾患の予防または治療剤
US7858756B2 (en) 2006-06-15 2010-12-28 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
EP2594586B1 (fr) 2006-09-01 2014-08-27 ZymoGenetics, Inc. Anticorps monoclonaux IL-31 et procédés d'utilisation
BRPI0720280A2 (pt) 2006-12-11 2014-01-28 Wyeth Corp Métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13
CN101600456A (zh) * 2006-12-11 2009-12-09 惠氏公司 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物
WO2008100995A1 (fr) 2007-02-14 2008-08-21 Vaccinex, Inc. Anticorps humains anti-cd100
EP2059534B1 (fr) 2007-02-23 2012-04-25 Schering Corporation Anticorps obtenus par génie génétique dirigés contre l'il-23p19
WO2008114733A1 (fr) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. Anticorps anti-claudine-4
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
CN101687038A (zh) 2007-07-10 2010-03-31 霍夫曼-拉罗奇有限公司 新型制剂
EP4339294A2 (fr) * 2007-09-26 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Procédé de modification du point isoélectrique d'un anticorps par substitution d'acide aminé dans cdr
CA3139492A1 (fr) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Region constante d'anticorps modifie
AR068564A1 (es) 2007-09-26 2009-11-18 Chugai Pharmaceutical Co Ltd Anticuerpo anti- receptor de il-6 (interleuquina 6)
AU2008332271C1 (en) 2007-12-05 2014-04-24 Chugai Seiyaku Kabushiki Kaisha Anti-NR10 antibody and use thereof
JP5475460B2 (ja) 2007-12-05 2014-04-16 中外製薬株式会社 掻痒症治療剤
SI2796466T1 (en) 2007-12-07 2018-01-31 Zymogenetics, Inc. Molecules of Humanized Specifics Specifiable for IL-31
KR20160062207A (ko) 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP3075386B1 (fr) 2009-06-17 2019-10-16 BioMarin Pharmaceutical Inc. Formulations pour enzymes lysosomales
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
SG10201701798TA (en) 2012-09-07 2017-04-27 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
US9198898B2 (en) * 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2014208645A1 (fr) * 2013-06-28 2014-12-31 中外製薬株式会社 Méthode de prédiction de la réponse d'un patient atteint d'une maladie prurigineuse à une thérapie avec antagoniste de l'il-31
KR20170134748A (ko) 2015-04-14 2017-12-06 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
GB201703063D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
WO2018156367A1 (fr) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anticorps anti-il31 à usage vétérinaire
BR112019021364A2 (pt) 2017-04-11 2020-05-05 Kiniksa Phamaceuticals Ltd formulação estável de anticorpo anti-osmr
EP3797752A4 (fr) 2018-05-21 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Formulation lyophilisée scellée dans un flacon en verre
CN114728064A (zh) 2019-11-20 2022-07-08 中外制药株式会社 含抗体制剂
CA3189847A1 (fr) 2020-09-01 2022-03-10 Naoki Fukazawa Composition pharmaceutique pour la prevention et/ou le traitement du prurit en dialyse contenant comme principe actif un antagoniste de l'il-31

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734549A1 (fr) * 2011-07-21 2014-05-28 Zoetis LLC Anticorps monoclonal dirigé contre l'interleukine-31

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDREA MONTES-TORRES ET AL: "Biological Treatments in Atopic Dermatitis", JOURNAL OF CLINICAL MEDICINE, vol. 4, no. 4, 3 April 2015 (2015-04-03), pages 593 - 613, XP055517123, DOI: 10.3390/jcm4040593 *
ANONYMOUS: "Randomized, double-blind, placebo-controlled, multi-center, multi-dose Phase II study of anti-interleukin-31 receptor A monoclonal antibody CIM331 (nemolizumab) in patients with moderate-to-severe atopic dermatitis", 4 March 2016 (2016-03-04), XP055517070, Retrieved from the Internet <URL:https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_ref_list.xml_show_ficha_ref?p_ref_id=2473202> [retrieved on 20181018] *
ANONYMOUS: "Safety and tolerability of a humanized monoclonal antibody to the Interleukin-31 receptor; results of a phase I, single ascending dose study, in healthy volunteers and patients with atopic dermatitis", 3 October 2013 (2013-10-03), XP055517067, Retrieved from the Internet <URL:https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_ref_list.xml_show_ficha_ref?p_ref_id=2061834> [retrieved on 20181018] *
O. NEMOTO ET AL: "The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-co", BRITISH JOURNAL OF DERMATOLOGY, vol. 174, no. 2, 19 December 2015 (2015-12-19), UK, pages 296 - 304, XP055517114, ISSN: 0007-0963, DOI: 10.1111/bjd.14207 *
THOMAS RUZICKA ET AL: "Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis", THE NEW ENGLAND JOURNAL OF MEDICINE, - NEJM -, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 376, 1 March 2017 (2017-03-01), pages 826 - 835, XP009195193, ISSN: 0028-4793, DOI: 10.1056/NEJMOA1606490 *

Also Published As

Publication number Publication date
WO2016167263A1 (fr) 2016-10-20
RU2017138551A3 (fr) 2019-09-30
JP2023134842A (ja) 2023-09-27
MX2021013139A (es) 2021-11-25
JP6887212B2 (ja) 2021-06-16
US20200102396A1 (en) 2020-04-02
JP6654967B2 (ja) 2020-02-26
KR20170134748A (ko) 2017-12-06
US20180079817A1 (en) 2018-03-22
EP3284480A1 (fr) 2018-02-21
US11773173B2 (en) 2023-10-03
JP2020075937A (ja) 2020-05-21
MA43918A (fr) 2018-12-05
TWI738648B (zh) 2021-09-11
BR112017022101A2 (pt) 2018-07-31
MX2017013141A (es) 2018-02-21
TW201642905A (zh) 2016-12-16
TW202146048A (zh) 2021-12-16
JP2021105051A (ja) 2021-07-26
TWI826814B (zh) 2023-12-21
US10544227B2 (en) 2020-01-28
JP2017160178A (ja) 2017-09-14
RU2017138551A (ru) 2019-05-14
TW202327654A (zh) 2023-07-16
CN107614016B (zh) 2022-06-17
CN107614016A (zh) 2018-01-19
CA2980992A1 (fr) 2016-10-20
JP2021193124A (ja) 2021-12-23
RU2749512C2 (ru) 2021-06-11
CA2980992C (fr) 2024-01-23

Similar Documents

Publication Publication Date Title
EP3284480A4 (fr) Composition pharmaceutique pour la prévention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l&#39;il-31
EP3386484A4 (fr) Compositions et procédés permettant d&#39;administrer des agents thérapeutiques
EP3031826A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
EP3111931A4 (fr) Composition pharmaceutique pour le traitement du cancer contenant du gossypol et de la phénformine en tant que principes actifs
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
EP3153170A4 (fr) Méthode d&#39;utilisation de dérivés de la quinoléine pour le traitement des sarcomes des tissus mous, applications et composition pharmaceutique les contenant destinée au traitement des sarcomes des tissus mous
EP3381473A4 (fr) Composition pharmaceutique utilisée pour réduire la graisse localisée et utilisation de la composition pharmaceutique
EP3694832A4 (fr) Formulation pharmaceutique à libération prolongée et procédés de traitement
EP3294761A4 (fr) Compositions et méthodes de traitement et de prévention de l&#39;infection pare. coli
EP3093023A4 (fr) Composition pharmaceutique pour le traitement du cancer et préparation pharmaceutique pour le traitement du cancer contenant ladite composition en tant que substance active
EP3380525A4 (fr) Formulations pharmaceutiques et leurs procédés d&#39;utilisation
EP3336100A4 (fr) Peptide ayant pour effet de prévenir ou traiter des maladies du système nerveux central et composition pharmaceutique pour la prévention et le traitement de maladies du système nerveux central, contenant ce dernier en tant que principe actif
EP3518918A4 (fr) Méthodes et compositions pharmaceutiques pour le traitement de la stéatohépatite non alcoolique
EP3231436A4 (fr) Composition pharmaceutique pour la prévention ou le traitement d&#39;une maladie métabolique, comprenant des bactéries bacteroides acidifaciens utilisées comme principe actif efficace
IL250306B (en) Heterocyclyl-carbonyl derivatives of indazole and pyrazolo-pyridine and medicinal preparations containing them
EP3378491A4 (fr) Composition pharmaceutique pour traiter ou prévenir la stéatohépatite non alcoolique (nash)
EP3485887A4 (fr) Composition pharmaceutique de tecovirimat à administration par voie intraveineuse et sa méthode de préparation
EP3378484A4 (fr) Composition pharmaceutique pour le traitement de la fibrose cardiaque
HK1217303A1 (zh) 種治療白血病的藥物組合物及其製備方法
EP3570835A4 (fr) Méthodes et compositions pharmaceutiques pour la prévention ou le traitement d&#39;affections dermiques immuno-inflammatoires
EP3277269A4 (fr) Méthodes de prévention et de traitement du syndrome cardiométabolique et compositions utilisées pour ces dernières
HK1245094A1 (zh) 一種治療抑鬱症的藥物組合物及其製備方法
IL257336B (en) Pharmaceutical compounds and preparations for the prevention or treatment of parasitic diseases
EP3503885A4 (fr) Composition pharmaceutique et procédés d&#39;utilisation
EP3532052A4 (fr) Conception et composition de formulations pharmaceutiques stabilisées par des cellules

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171113

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20181102

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/20 20060101ALI20181026BHEP

Ipc: C07K 16/28 20060101ALI20181026BHEP

Ipc: C07K 16/24 20060101ALI20181026BHEP

Ipc: A61P 17/00 20060101ALI20181026BHEP

Ipc: A61K 39/395 20060101ALI20181026BHEP

Ipc: A61K 45/00 20060101AFI20181026BHEP

Ipc: A61P 17/04 20060101ALI20181026BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200309

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS